{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:42:46Z","timestamp":1792896166383,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T00:00:00Z","timestamp":1651449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011218","name":"Sandoz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011218","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["11A9320N"],"award-info":[{"award-number":["11A9320N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone Reports"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.bonr.2022.101582","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T12:17:55Z","timestamp":1651666675000},"page":"101582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases"],"prefix":"10.1016","volume":"16","author":[{"given":"Jolan","family":"Dupont","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley","family":"Appermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Dejaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Wauters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u00ebl R.","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien","family":"Gielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bonr.2022.101582_bb0005","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J. Bone Miner. Res Off. J. Am. Soc. Bone Miner. Res."},{"key":"10.1016\/j.bonr.2022.101582_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10010152","article-title":"Denosumab discontinuation and the rebound phenomenon: a narrative review","volume":"10","author":"Anastasilakis","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bonr.2022.101582_bb0015","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jocd.2021.01.006","article-title":"Efficacy of antiosteoporotic medications in patients with rebound-associated fractures after denosumab discontinuation","volume":"24","author":"Anastasilakis","year":"2021","journal-title":"J. Clin. Densitom."},{"key":"10.1016\/j.bonr.2022.101582_bb0020","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jocd.2020.10.014","article-title":"Progression of rebound-associated vertebral fractures following denosumab discontinuation despite reinstitution of treatment: suppressing increased bone turnover may not be enough","volume":"24","author":"Anastasilakis","year":"2021","journal-title":"J. Clin. Densitom."},{"key":"10.1016\/j.bonr.2022.101582_bb0025","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/jbmr.4335","article-title":"Fractures after denosumab discontinuation: a retrospective study of 797 cases","volume":"36","author":"Burckhardt","year":"2021","journal-title":"J. Bone Miner. Res Off. J. Am. Soc. Bone Miner. Res."},{"key":"10.1016\/j.bonr.2022.101582_bb0030","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO clinical practice guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bonr.2022.101582_bb0035","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bonr.2022.101582_bb0040","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J. Bone Miner. Res Off. J. Am. Soc. Bone Miner. Res."},{"key":"10.1016\/j.bonr.2022.101582_bb0045","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10396","article-title":"Failure of Oral risedronate therapy to prevent spontaneous vertebral fracture in a patient ceasing denosumab: a cautionary case","volume":"4","author":"Davidoff","year":"2020","journal-title":"JBMR Plus"},{"key":"10.1016\/j.bonr.2022.101582_bb0050","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.3722","article-title":"Relationship between bone mineral density t-score and nonvertebral fracture risk over 10 years of denosumab treatment","author":"Ferrari","year":"2019","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"key":"10.1016\/j.bonr.2022.101582_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2019.02.007","article-title":"Spontaneous vertebral fractures after denosumab discontinuation: a case collection and review of the literature","author":"Florez","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.bonr.2022.101582_bb0060","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2165\/11598090-000000000-00000","article-title":"Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours","volume":"51","author":"Gibiansky","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bonr.2022.101582_bb0065","article-title":"Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: a case report","volume":"13","author":"Kashii","year":"2020","journal-title":"Bone Rep."},{"key":"10.1016\/j.bonr.2022.101582_bb0070","article-title":"Effect of risedronate on bone loss at discontinuation of denosumab","volume":"13","author":"Laroche","year":"2020","journal-title":"Bone Rep."},{"key":"10.1016\/j.bonr.2022.101582_bb0075","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases","volume":"25","author":"Lipton","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.bonr.2022.101582_bb0080","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1210\/jc.2013-3795","article-title":"Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis","volume":"99","author":"Mandema","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bonr.2022.101582_bb0085","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11657-019-0676-0","article-title":"Second rebound-associated vertebral fractures after denosumab discontinuation","volume":"15","author":"Niimi","year":"2020","journal-title":"Arch. Osteoporos."},{"key":"10.1016\/j.bonr.2022.101582_bb0090","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bonr.2022.101582_bb0095","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.maturitas.2020.05.006","article-title":"The Belgian Bone Club 2020 guidelines for the management of osteoporosis in postmenopausal women","volume":"139","author":"Sanchez-Rodriguez","year":"2020","journal-title":"Maturitas"},{"key":"10.1016\/j.bonr.2022.101582_bb0100","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/jbmr.4098","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial","volume":"35","author":"S\u00f8lling","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bonr.2022.101582_bb0105","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2165\/11594240-000000000-00000","article-title":"Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis","volume":"50","author":"Sutjandra","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bonr.2022.101582_bb0110","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S1470-2045(20)30559-3","article-title":"Treatment of multiple myeloma-related bone disease: recommendations from the bone working Group of the International Myeloma Working Group","volume":"22","author":"Terpos","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bonr.2022.101582_bb0115","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.bonr.2022.101582_bb0120","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","author":"Tsourdi","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bonr.2022.101582_bb0125","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.mayocpiqo.2019.02.003","article-title":"Rebound vertebral fractures in a patient with lung cancer after oncology-dose denosumab discontinuation: a cautionary tale","volume":"3","author":"Tyan","year":"2019","journal-title":"Mayo Clin. Proc. Innov. Qual. Outcomes"}],"container-title":["Bone Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352187222004168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352187222004168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T16:24:04Z","timestamp":1762446244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352187222004168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":25,"alternative-id":["S2352187222004168"],"URL":"https:\/\/doi.org\/10.1016\/j.bonr.2022.101582","relation":{},"ISSN":["2352-1872"],"issn-type":[{"value":"2352-1872","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases","name":"articletitle","label":"Article Title"},{"value":"Bone Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bonr.2022.101582","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101582"}}